Document is current
Any future updates will be listed below
-
Authors
Kauzonas, Evaldas https://orcid.org/0009-0001-8380-9686
Torisson, Gustav https://orcid.org/0000-0001-9012-2068
Merlo, Juan https://orcid.org/0000-0001-8379-9708
Perez, Raquel https://orcid.org/0000-0002-6273-1656
Tabah, Alexis https://orcid.org/0000-0003-3513-2778
Buetti, Niccolò https://orcid.org/0000-0002-8096-1834
Ruckly, Stéphane
Barbier, François
Timsit, Jean-François https://orcid.org/0000-0002-6063-7383
Sjövall, Fredrik https://orcid.org/0000-0001-5612-0325
,
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 30 September 2025
First Online: 20 October 2025
Declarations
:
: E.K., G.T., J.M., R.P., A.T., N.B., S.R., and F.S. reported no competing interests. F.B. reported lecture fees and research grants from MSD, conference invitations from Pfizer, and consulting fees from Shionogi and Advanz Pharma. J-F.T. reported advisory board participation for Merck, Biomerieux, Pfizer, Roche diagnostic, Shionogi, Menarini, and research grants to his research unit from Merck and Pfizer.
